{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-24-000003","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.666360+00:00","generated_at":"2026-06-07T02:31:36.775517+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeneDx prelim Q4 revenue >$57M, exome/genome rev +63% YoY; cash burn -51% YoY","bullets":["Q4 continuing ops revenue >$57M (+24% YoY); exome/genome revenue >$38M (+63% YoY).","Exome/genome test results 15,663 in Q4 (+99% YoY), now 27% of total test volume.","Cash and equivalents $131M as of Dec 31, 2023.","Q4 cash burn $33M, down 51% YoY and 21% sequentially; reiterates 2025 profitability path.","Full year 2023 continuing ops revenue expected at least $193M; exceeded revised guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-24-000003","json":"https://secwatch.observer/filing/0001818331-24-000003.json","markdown":"https://secwatch.observer/filing/0001818331-24-000003.md","text":"https://secwatch.observer/filing/0001818331-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/wgs-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:31:36.775517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40ea1c127998bd84109f6357c6d81b22dbb0dfd7","claim":"GeneDx Holdings Corp. reported full year 2023 results: revenue at least $193 million. Guidance reaffirmed.","evidence_excerpt":"Management expects GeneDx to report: • revenues of at least $193 million for full year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"at least $193 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"8614fbdbf476bb2b7e4cdec54b66e9f5e197fe83","claim":"GeneDx Holdings Corp. reported fourth quarter of 2023 results: revenue at least $57 million. Guidance reaffirmed.","evidence_excerpt":"Financial Results (Unaudited) Continuing Operations Results: 1 Management expects GeneDx to report: • revenues of at least $193 million for full year 2023 • revenues of at least $57 million in the fourth quarter, an increase of 24% year-over-year and 13% sequentially; • exome and genome test revenues of at least $38 million in the fourth quarter, an increase of 63%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2023"},{"label":"Revenue","value":"at least $57 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}